MedTrace Logo

Assessment of Brain Cognitive Impairment in Breast Cancer

NCT05305092 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2022-07-13

No results posted yet for this study

Summary

To explore the cognitive impairment caused by chemotherapy and endocrine therapy in premenopausal breast cancer patients and to find biomarkers with early predictive effect on this cognitive impairment by using multimodal integrated PET/MRI technology combined with psychobehavioral technology.

Conditions

Interventions

DEVICE

PET/MRI, psychobehavioral tests and questionnaires, serum biomarkers and stool sample

Neuroimaging data were collected by integrated PET/MRI machine, and collected the psychobehavioral data, the serum and stool samples of participants.

Sponsors & Collaborators

  • Xi'an Jiaotong University

    collaborator OTHER

  • Tang-Du Hospital

    lead OTHER

Principal Investigators

  • Menghui Yuan, phd · Tang-Du Hospital

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2027-05-30
Completion
2027-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305092 on ClinicalTrials.gov